Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal

References

• Davies NM. COX-2 inhibitors and cardiac toxicity: getting to the heart of the matter. J. Pharm. Sci.7(3), 332–336 (2004).
   Web of Science ®Google Scholar
• Davies NM, McLachlan AJ. Considerations of cyclooxygenase-2 inhibitors. Clin. Geriatrics8(6), 49–62 (2000).
   Google Scholar
• Davies NM, Wallace JL. Non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J. Gastroenterol.32(2), 127–133 (1997).
   PubMed Web of Science ®Google Scholar
• Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res. Ther.7(4), S14–S22 (2005).
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Breyer MD, Strand CV et al. Cardiovascular effects of selective Cox-2 inhibition: is there a class effect? The international Cox-2 Study group. J. Rheumatol.33, 1403–1418 (2006).
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FtizGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest.116(1), 4–15 (2006).
   PubMed Web of Science ®Google Scholar
• Fries S, Grosser T, Price TS et al. Marked interindividual variability in the response to selective inhibitors of cyxloooxygenase-2. Gastroenterology130, 55–64 (2006).
   PubMed Web of Science ®Google Scholar
• Davies NM, Wallace JL. Selective inhibitors of cyclooxygenase 2 – potential in elderly patients. Drugs Aging9(6), 406–417 (1996).
   PubMed Web of Science ®Google Scholar
• Davies NM, Skjodt NM. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin. Pharmacokinet.38(5), 377–392 (2000).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med.343(21), 1520–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N. Engl. J. Med.352(11), 1092–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA286(8), 954–959 (2001).
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs. Arch. Intern. Med.165(9), 978–984 (2005).
   PubMed Web of Science ®Google Scholar
• Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann. Intern. Med.142(7), 481–489 (2005).
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med.352(11), 1081–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg.125(6), 1481–1492 (2003).
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am. J. Cardiol.92(4), 411–418 (2003).
   PubMed Web of Science ®Google Scholar
• White WB, Verburg KM, Whelton A. The cyclo-oxygenase-2 specific inhibitor valdecoxib is not associated with an increased risk of cardiovascular thrombotic events in arthritis patients. J. Am. Coll. Cardiol.41(Suppl. A), 525A (2003A) (Abstract 1095–51).
   Google Scholar
• Whelton A, Kent JD, Recker DP. No difference in thrombotic events in rheumatoid arthritis patients: valdecoxib vs. naproxen and placebo. Arthritis Rheum.46, 512 (2002) (Abstract 1370).
   Google Scholar
• Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet364(9435), 675–684 (2004).
   PubMed Web of Science ®Google Scholar
• Curtis SP, Mukhopadhyay S, Ramey D, Reicin A. Cardiovascular safety summary associated with the etoricoxib development program [abstract]. Arthritis Rheum.48(Suppl. 9), 1600 (2003).
   Google Scholar
• Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol.90(9), 959–963 (2003).
   Web of Science ®Google Scholar
• Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verbury KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther.8(2), 85–95 (2001).
   PubMedGoogle Scholar
• Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Br. Med. J.330(7504), 1–6 (2005).
   PubMedGoogle Scholar
• Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet363(9423), 1751–1756 (2004).
   PubMed Web of Science ®Google Scholar
• Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Am. J. Manag. Care8(Suppl. 15), S401–S413 (2002).
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and Type 2 diabetes mellitus. Arch. Intern. Med.165(2), 161–168 (2005).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation109(17), 2068–2073 (2004).
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med.142(3), 157–164 (2005).
   PubMed Web of Science ®Google Scholar
• Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. J. Cardiol.89(8), 204–209 (2002).
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al, for the Celecoxib Long-Term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA284(10), 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• White WB, Kent J, Taylor A, Verbury KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE-inhibitors. Hypertension39(4), 929–934 (2002).
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am. J. Cardiol.89(4), 425–430 (2002).
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352(11), 1071–1080 (2005).
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hiu R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet365(9458), 475–481 (2005).
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein MC, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet360(9339), 1071–1073 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation109(24), 3000–3006 (2004).
   PubMed Web of Science ®Google Scholar
• Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med.162(10), 1111–1115 (2002).
   PubMed Web of Science ®Google Scholar
• Jüni P, Nartey L, Reichenbach S, Sterchi R, Diepppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet364, 2021–2029 (2004).
   Google Scholar
• Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2-inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. Br. Med. J.332(7553), 1302–1308 (2006).
   PubMed Web of Science ®Google Scholar
• Bolli R, Shinmura K, Tang XL et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc. Res.55(3), 506–519 (2002).
   PubMed Web of Science ®Google Scholar
• McEntegart A, Capell HA, Creran C, Rumley A, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology40(6), 640–644 (2001).
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med.353(22), 2373–2383 (2005).
   PubMed Web of Science ®Google Scholar
• Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tongnoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. JAMA295(3), 306–313 (2006).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med.352(13), 1293–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Mitka M. Aspirin, “super aspirin” use in women for cardioprevention probed. JAMA295(1), 20–21 (2006).
   PubMed Web of Science ®Google Scholar
• Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation108(10), 1191–1195 (2003).
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med.345(25), 1809–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med.352(3), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Widlansky ME, Price DT, Gokee N et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension42(3), 310–315 (2003).
   PubMed Web of Science ®Google Scholar
• Chenevard R. Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation107(3), 405–409 (2003).
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA284(10), 1247–1255 (2000).
   PubMed Web of Science ®Google Scholar
• Hennan JK, Huang J, Barrett TD et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation104(7), 820–825 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr. Pharm. Des.11(14), 1795–1804 (2005).
   PubMed Web of Science ®Google Scholar
• White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension39(4), 929–934 (2002).
   PubMed Web of Science ®Google Scholar
• Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BHC, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med.158, 1108–1112 (1998).
   PubMed Web of Science ®Google Scholar
• Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch. Intern. Med.160, 777–784 (2000).
   PubMed Web of Science ®Google Scholar
• Feenstra J, Heerdink ER, Grobee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure. Arch. Intern. Med.162, 265–270 (2002).
   PubMed Web of Science ®Google Scholar
• Boers M, Dijkmans BA, Breedveld FC et al. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. Br. J. Rheumatol.30(1), 56–59 (1991).
   PubMedGoogle Scholar
• Fullerton T, Sica DA, Blum RA. Evaluation of the renal protective effect of misoprostol in elderly, osteoarthritic patients at risk for nonsteroidal anti-inflammatory drug-induced renal dysfunction. J. Clin. Pharmacol.33(12), 1225–1232 (1993).
   PubMed Web of Science ®Google Scholar
• Wilkie ME, Davies GR, Marsh FP, Rampton DS. Effects of indomethacin and misoprostol on renal function in healthy volunteers. Clin. Nephrol.38(6), 334–337 (1992).
   PubMed Web of Science ®Google Scholar
• Nesher G, Sonnenblick M, Dwolatzky T. Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients. J. Rheumatol.22(4), 713–716 (1995).
   PubMed Web of Science ®Google Scholar
• Weir MR, Klassen DK, Hall PS et al. Minimization of indomethacin-induced reduction in renal function by misoprostol. J. Clin. Pharmacol.31(8), 729–735 (1991).
   PubMed Web of Science ®Google Scholar
• Antillon M, Cominelli F, Lo S et al. Effects of oral prostaglandins on indomethacin-induced renal failure in patients with cirrhosis and ascites. J. Rheumatol. Suppl.20, 46–49 (1990).
   PubMedGoogle Scholar
• Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J. Hepatol.11(2), 153–158 (1990).
   PubMed Web of Science ®Google Scholar
• Gines A, Salmeron JM, Gines P et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J. Hepatol.17(2), 220–226 (1993).
   PubMed Web of Science ®Google Scholar
• Hsia HC, Lin HC, Tsai YT et al. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Scand. J. Gastroenterol.30(12), 1194–1199 (1995).
   PubMed Web of Science ®Google Scholar
• Wong F, Massie D, Hsu P, Dudley F. The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis. Am. J. Gastroenterol.90(9), 1465–1470 (1995).
   PubMed Web of Science ®Google Scholar
• Wong F, Massie D, Hsu P, Dudley F. The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis. J. Hepatol.23(1), 1–7 (1995).
   PubMedGoogle Scholar
• Wong F, Massie D, Hsu P, Dudley F. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology106(3), 658–663 (1994).
   PubMed Web of Science ®Google Scholar
• Ackerman Z, Cominelli F, Reynolds TB. Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study. Am. J. Gastroenterol.97(8), 2033–2039 (2002).
   PubMed Web of Science ®Google Scholar
• Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum.47, 36–43 (2002).
   PubMed Web of Science ®Google Scholar
• Scheiman JM. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention. Rev. Gastroenterol. Disord.5(Suppl. 2), 39–49 (2005).
   PubMedGoogle Scholar
• Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet359(9300), 14–22 (2002).
   PubMed Web of Science ®Google Scholar
• Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet359(9300), 9–13 (2002).
   Google Scholar
• Hawkey CJ. What consideration should be given to helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers? Eur. J. Gastroenterol. Hepatol.12(Suppl. 1), S17–S20 (2000).
   Google Scholar
• Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis. Colon Rectum28(12), 1311–1321 (1995).
   Google Scholar
• Davies NM, Jamali F, Skeith KH. Non-steroidal antiinflammatory drug (NSAID)-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Arthritis Rheum.39(2), 321–324 (1996).
   PubMedGoogle Scholar
• Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J. Pharm. Pharm. Sci.2(1), 5–14 (1999).
   PubMed Web of Science ®Google Scholar
• Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int. J. Clin. Pract.59(10), 1210–1227 (2005).
   PubMed Web of Science ®Google Scholar
• Spiegel BMR, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with coxibs vs NSAID + PPI: a meta-analysis. Am. J. Med.119(5), 448.e27–448.e36 (2006).
   Google Scholar
• Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology45, 606–613 (2006).
   PubMed Web of Science ®Google Scholar
• Robert A, Schultz JR, Nezamis JE, Lancaster C. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology70(3), 359–370 (1976).
   PubMed Web of Science ®Google Scholar
• Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Br. Med. J.329(7472), 948 (2004).
   PubMed Web of Science ®Google Scholar
• Malagelada JR, Rodriguez de la Serna A, Dammann HG et al. Sucralfate therapy in NSAID bleeding gastropathy. Clin. Gastroenterol. Hepatol.1(1), 51–56 (2003).
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL et al. SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am. J. Med.119(3), 255–266 (2006).
   PubMed Web of Science ®Google Scholar
• Dentali F, Douketis JD, Woods K et al. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann. Pharmacother.40(7–8), 1241–1247 (2006).
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal anti-inflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum.53(2), 185–197 (2005).
   PubMed Web of Science ®Google Scholar
• Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst. Rev. (4), CD002296 (2002).
   Google Scholar
• Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? Rheumatology45(5), 606–613 (2006).
   PubMed Web of Science ®Google Scholar
• Hur C, Chan AT, Tramontano C, Gazelle GS. Coxibs versus Combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits and costs. Ann. Pharmacotherapy40(6), 1052–1063 (2006).
   PubMed Web of Science ®Google Scholar
• You JH, Lau W, Lee IY et al.Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients – a cost-effectiveness analysis. Int. J. Clin. Pharmacol. Ther.44(4), 149–153 (2006).
   PubMed Web of Science ®Google Scholar
• Tannenbaum H, Bombardier C, Davis P, Russell AS. Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference [see comment]. Consensus Development Conference. J. Rheumatol.33(1), 14–157 (2006), erratum appears in J. Rheumatol.33(2), 440 (2006).
   Google Scholar
• Wilcox Cm, Allison J, Bezuly K et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin. Gastroenterol. Hepatol. (2006) (Epub ahead of print).
   Google Scholar
• Zeilhofer HU, Brune K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol. Sci.27(9), 467–474 (2006).
   PubMed Web of Science ®Google Scholar